Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Buprenorphine transdermal system 96-hour versus 72-hour application interval in severe cancer pain
2008-003592-48Phase 3Completed
- Sponsor
- Novosis
- Start
- Jan 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of buprenorphine in cancer pain (2 arms), sponsored by Novosis. Started Jan 2009; status: completed.
02
Drugs
buprenorphine
03
Conditions
cancer pain
Beyond the preview
Go deeper on 2008-003592-48.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-003592-48.